Home » Stocks » ANGN

Angion Biomedica Corp. (ANGN)

Stock Price: $13.44 USD -0.16 (-1.18%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 398.67M
Revenue (ttm) 2.39M
Net Income (ttm) n/a
Shares Out 23.44M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $13.44
Previous Close $13.60
Change ($) -0.16
Change (%) -1.18%
Day's Open 13.40
Day's Range 13.25 - 13.73
Day's Volume 44,495
52-Week Range 12.45 - 26.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...

3 weeks ago - GlobeNewsWire

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion's AKI-002-15 study,...

1 month ago - Business Wire

Topline data expected in the second half of 2021 Topline data expected in the second half of 2021

1 month ago - GlobeNewsWire

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

2 months ago - GlobeNewsWire

Topline data expected in the first half of 2021 Topline data expected in the first half of 2021

2 months ago - GlobeNewsWire

UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

2 months ago - GlobeNewsWire

UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

3 months ago - GlobeNewsWire

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of n...

4 months ago - GlobeNewsWire

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of no...

4 months ago - GlobeNewsWire

Angion Biomedica, a Phase 3 biotech developing small molecule therapies for acute organ injuries, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company had p...

4 months ago - NASDAQ

Angion Biomedica Corp. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

About ANGN

Angion Biomedica is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our pipeline of product candidates has been developed internally and is the result of over 20 years of in-house research by a team that has made seminal contributions to the understanding of HGF and fibrotic pathways. Our lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that we are currently evaluating in mul... [Read more...]

Industry
Biotechnology
IPO Date
Feb 5, 2021
CEO
Jay R. Venkatesan, M.D.
Employees
66
Stock Exchange
NASDAQ
Ticker Symbol
ANGN
Full Company Profile

Financial Performance

In 2020, ANGN's revenue was $2.88 million, an increase of 93.68% compared to the previous year's $1.49 million. Losses were -$80.11 million, 97.0% more than in 2019.

Financial Statements